The Trump administration is preparing to announce 100% tariffs on pharmaceutical companies that haven't secured pricing deals with the White House, potentially as soon as Thursday. The tariffs stem from a Section 232 investigation citing national security grounds. Major drugmakers including Pfizer, Eli Lilly, AstraZeneca, Novo Nordisk, and Johnson & Johnson have already secured three-year reprieves by agreeing to most-favored-nation pricing. The tariff threat is part of a broader pricing strategy that includes the TrumpRx.gov platform for comparing discounted drug prices.

Multiple major M&A transactions are underway across various sectors. Papa John's received a $1.5 billion privatization proposal from Irth Capital Management backed by Brookfield Asset Management. Shell sold Jiffy Lube to Monomoy Capital Partners for $1.3 billion. Meta acquired AI social network Moltbook, while Google completed its $32 billion acquisition of cloud security platform Wiz. Other notable deals include Agilent acquiring Biocare Medical for $950 million and Universal Health Services acquiring Talkspace for $835 million. Meanwhile, several retailers including Eddie Bauer and Saks Global are closing stores amid bankruptcy proceedings.

Universal Health Services announced a definitive agreement to acquire Talkspace for $5.25 per share, valuing the deal at approximately $835 million. The acquisition aims to strengthen UHS's outpatient strategy and expand access to virtual behavioral healthcare through Talkspace's platform of 6,000 licensed professionals. Talkspace generated $229 million in revenue in 2025 from over 1.6 million therapy and psychiatry sessions.

Tech stocks tumbled Thursday as investors sold off following Nvidia's blockbuster earnings results, with the company dropping 4.5% and dragging the semiconductor sector lower. The VIX volatility index rallied over 10%, while the Magnificent 7 stocks collectively lost roughly $400 billion in market capitalization. Energy outperformed with a 0.8% gain, while technology led declines with a 2% drop. Michael Burry warned that Nvidia's purchase commitments resemble dot-com bubble levels.

Universal Health Services, Inc. (NYSE: UHS) announced that its Board of Directors approved a cash dividend of $0.20 per share payable on March 16, 2026 to shareholders of record as of March 2, 2026.

The U.S. mental health treatment market is valued at $118 billion and is projected to grow significantly through 2030, driven by increased awareness, technology integration, and rising mental illness prevalence affecting 61 million Americans. The sector faces challenges including a shortage of mental health professionals and access gaps, while teletherapy and mental health apps have created a $2 billion market segment. Major players include facility operators like Acadia Healthcare and Universal Health Services, alongside digital platforms such as Lyra Health, Spring Health, Headspace, Calm, Talkspace, and BetterHelp.

The article highlights three healthcare stocks trading at attractive valuations: DaVita, Merck, and Universal Health Services, which offer potential investment opportunities despite current market challenges.

Universal Health Services reported strong Q2 2025 financial results, with revenue of $4.28 billion and EPS of $5.35, exceeding analyst estimates. The company benefited from higher Medicaid reimbursements and raised its full-year guidance, though facing potential regulatory challenges.

Universal Health Realty Income Trust reported a slight decline in net income and funds from operations in Q2 2025, with minor revenue growth and a cautious dividend increase amid challenging healthcare operating environment.

The article explores three high-dividend healthcare REITs that have demonstrated resilience during the COVID-19 pandemic, focusing on senior housing and medical office properties with attractive dividend yields ranging from 6.4% to 7.1%.

Universal Health Realty Income Trust offers a high 7.4% dividend yield, with a 40-year history of annual dividend increases. While attractive for income investors, it has slower dividend growth and potential conflicts of interest due to external management.

The article compares Johnson & Johnson's dividend performance with Universal Health Realty Income Trust, highlighting the latter's significantly higher dividend yield of 7.4% versus J&J's 3.4%, and suggesting it might be more attractive for income-focused investors.